Pharvaris (PHVS) furnishes Q3 2025 results and interim filings

Rhea-AI Filing Summary

Pharvaris N.V. submitted a Form 6-K summarizing that it has furnished a press release reporting financial results and other business updates for the three and nine months ended September 30, 2025. The press release is attached as Exhibit 99.1 and is designated as furnished, not filed, under the Exchange Act. The filing also attaches Management’s Discussion and Analysis as Exhibit 99.2 and unaudited condensed consolidated interim financial statements as Exhibit 99.3 for the same periods and as of December 31, 2024. Exhibits 99.2 and 99.3 are incorporated by reference into Pharvaris’s existing Form F-3 and Form S-8 registration statements.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-40010

Pharvaris N.V.

(Translation of registrant’s name into English)

Emmy Noetherweg 2

2333 BK Leiden

The Netherlands
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

PHARVARIS N.V.

On November 12, 2025, Pharvaris N.V. issued a press release reporting financial results and other business updates for the three and nine months ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act. Exhibits 99.2 and 99.3 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Number 333-273757, 333-277705 and 333-278650) and Form S-8 (Registration Number 333-252897) of Pharvaris N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release, dated November 12, 2025, (Financial results).
99.2		Management’s Discussion and Analysis of Financial Condition and Results of Operations as of and for the Three and Nine Months Ended September 30, 2025 and 2024.
99.3		Unaudited Condensed Consolidated Interim Financial Statements as of and for the Three and Nine Months Ended September 30, 2025 and 2024 and as of December 31, 2024.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PHARVARIS N.V.
Date: November 12, 2025	By:	/s/ Berndt Modig
	Name:	Berndt Modig
	Title:	Chief Executive Officer

FAQ

What did Pharvaris (PHVS) report in this Form 6-K?

Pharvaris N.V. reported that it issued a press release with financial results and other business updates for the three and nine months ended September 30, 2025, and furnished that release as Exhibit 99.1.

Which periods are covered by Pharvaris’s latest financial information?

The attached materials cover Pharvaris’s financial condition and results of operations for the three and nine months ended September 30, 2025 and 2024, and include interim financial statements as of December 31, 2024.

How are the exhibits to this Pharvaris Form 6-K treated under U.S. securities laws?

The press release in Exhibit 99.1 is furnished and not deemed filed under Section 18 of the Exchange Act, while Exhibits 99.2 and 99.3 are incorporated by reference into Pharvaris’s effective Form F-3 and Form S-8 registration statements.

Which Pharvaris registration statements are updated by this Form 6-K?

Exhibits 99.2 and 99.3 are incorporated by reference into Pharvaris’s registration statements on Form F-3 with Registration Numbers 333-273757, 333-277705 and 333-278650, and its Form S-8 with Registration Number 333-252897.

Who signed Pharvaris’s November 2025 Form 6-K?

The Form 6-K was signed on behalf of Pharvaris N.V. by Berndt Modig, who is identified as the company’s Chief Executive Officer.